版本:
中国

BRIEF-BioCryst reports additional positive results from second interim analysis of APEX-1 trial

May 25 BioCryst Pharmaceuticals Inc

* BioCryst reports additional positive results from the second interim analysis of its APEX-1 trial

* BioCryst Pharma - a pre-planned analysis of peripheral and abdominal attacks showed reductions in peripheral attacks of 74%, 54%, 90% compared with placebo

* BioCryst Pharmaceuticals Inc says oral BCX7353 once-daily for 28 days was generally safe and well tolerated in subjects with hae

* BioCryst Pharmaceuticals Inc says additionally, no significant laboratory abnormalities were observed in two lower dose groups

* BioCryst Pharmaceuticals Inc - there were no serious aes and no severe aes in APEX-1 trial

* BioCryst Pharmaceuticals - three subjects in bcx7353 350 mg treatment arm, two of which were previously reported, discontinued study drug before day 28

* BioCryst Pharmaceuticals Inc says most common treatment-emergent adverse events were common cold and diarrhea in trial Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐